A Phase 2 interventional study of TRK-170 and Placebo in Crohn's Disease, sponsored by Toray Industries, Inc. Completed at 13 sites in 13 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-06-12.
Sponsored by Toray Industries, Inc · Phase 2, Interventional, and Treatment
In Crohn's Disease Patients
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
This study's enrollment of 123 is above the median of 66 across 1,188 interventional studies indexed under Crohn Disease.
Browse Crohn Disease studies →Toray Industries, Inc is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: TRK-170
Drug: TRK-170
Drug: TRK-170
Drug: Placebo
Crohn's Disease Activity Index
8 weeks (treatment), 4 weeks (follow-up)
Time frame: 12 weeks
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Toray Industries, Inc